OncoMatch/Clinical Trials/NCT07125872

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Is NCT07125872 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CD19 t-haNK- IV Administration for relapsed b-cell non hodgkin lymphoma.

Phase 2RecruitingImmunityBio, Inc.NCT07125872Data as of May 2026

Treatment: CD19 t-haNK- IV Administration — Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 2 prior lines

Must have received: cytotoxic chemotherapy

Have completed ≥2 lines of cytotoxic chemotherapy

Must have received: anti-CD20 antibody (rituximab)

Have received rituximab or another anti-CD20 antibody

Cannot have received: anti-CD20 antibody

Exception: less than 2 weeks prior to cell infusion

Anti-CD20 antibody treatment less than 2 weeks prior to cell infusion

Cannot have received: allogeneic hematopoietic stem-cell transplantation

Exception: requiring ongoing systemic graft versus host disease (GvHD) therapy

History of allogeneic hematopoietic stem-cell transplantation (HSCT) requiring ongoing systemic graft versus host disease (GvHD) therapy

Cannot have received: allograft organ transplant

Exception: requiring immunosuppression

History of receiving allograft organ transplant requiring immunosuppression

Lab requirements

Blood counts

ANC ≥ 1000 cells/mm3; Platelet count ≥ 100,000 cells/mm3

Kidney function

Serum creatinine < 160 µmol/L

Liver function

Total bilirubin < 1.5 × ULN (unless Gilbert's syndrome or indirect hyperbilirubinemia); AST/ALT < 2.5 × ULN; ALP < 2.5 × ULN (or < 5 × ULN with bone metastases)

Inadequate organ function, evidenced by ... ANC < 1000 cells/mm3. Platelet count < 100,000 cells/mm3. Total bilirubin ≥ 1.5 × ULN (unless ...). AST/ALT ≥ 2.5 × ULN. ALP ≥ 2.5 × ULN (or ≥ 5 × ULN in participants with bone metastases). Serum creatinine ≥ 160 µmol/L.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify